Figure 5 : PCI-2471 and bortezomib increased survival in vivo in a neuroblastoma
mouse SMSKCNR xenograft model.

Mice were treated daily with either vehicle control, 12.5 mg/kg PCI-2471 IP, 0.5mg/kg bortezomib IP or
combination until tumors reached a maximum volume of 3cm3 (survival end point, p = 0.001).